| Chapter title |
Decitabine.
|
|---|---|
| Chapter number | 10 |
| Book title |
Small Molecules in Oncology
|
| Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, October 2009
|
| DOI | 10.1007/978-3-642-01222-8_10 |
| Pubmed ID | |
| Book ISBNs |
978-3-64-201221-1, 978-3-64-201222-8
|
| Authors |
Michael Daskalakis, Nadja Blagitko-Dorfs, Björn Hackanson, Daskalakis M, Blagitko-Dorfs N, Hackanson B |
| Editors |
Uwe M. Martens |
| Abstract |
The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy derivative, 5-aza-2'-deoxycytidine (decitabine, Dacogen, are the most widely used inhibitors of DNA methylation which trigger demethylation leading to a consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo. Although the antileukemic capacity of decitabine has been known for almost 40 years, its therapeutic potential in hematologic malignancies is still under intensive investigation. Multiple clinical trials have shown the promising activity of low-dose decitabine in AML, MDS, CML, and hemoglobinopathies, whereas its efficacy in solid tumors is rather limited.Clinical responses appear to be induced by both epigenetic alterations and the induction of cell-cycle arrest and/or apoptosis. Recent clinical trials have been investigating new dosing schedules, routes of administration, and combination of decitabine with other agents, including histone deacetylase (HDAC) inhibitors. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 17% |
| Researcher | 3 | 17% |
| Student > Master | 3 | 17% |
| Student > Bachelor | 2 | 11% |
| Student > Ph. D. Student | 2 | 11% |
| Other | 2 | 11% |
| Unknown | 3 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 11% |
| Biochemistry, Genetics and Molecular Biology | 2 | 11% |
| Chemistry | 2 | 11% |
| Agricultural and Biological Sciences | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 5 | 28% |